



The Microbiome Test from Genetic Analysis AS launched on a new technology platform GA-map® Dysbiosis Test kit now commercially available on the Luminex MAGPIX® system

OSLO, NORWAY – 1. February 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has successfully completed the development and CE-marking of the GA-map® Dysbiosis Test for the Luminex MAGPIX® instrument system. Today the Company proudly launches GA-map® on a new platform; MAGPIX®.

The MAGPIX® instrument is the most affordable instrument of the Luminex’s xMAP® instruments and it enables up to 50 plex using MagPlex® Microspheres. The MAGPIX® system is already a widely used platform and a large number of laboratories have already installed this system for performing other tests.

To launch the GA-map® Test on a new readout system will capture the large number of labs already having the system installed, and thus be of great importance for significantly increasing the addressable market for our high precision GA-map® Microbiome test. The more affordable MAGPIX® system will also increase the market size for GA in terms of lowering the cost barrier to install the test platform. Potential customers have for some years asked for GA-map® on the MAGPIX® instrument system and GA has now completed the develop and CE-marked the GA-map® Test on this well-known and easy to use instrument.

This will complement GA’s current offering on the Luminex LX200 instrument, and GA now has the potential to offer our GA-map® platform also to the thousands of diagnostics labs globally that are running these high quality MAGPIX® instruments.

The human microbiome market is accelerating both in terms of evidence-based research and pharma products launched. The market’s need for a clinical validated microbiome test is growing with this market. Thus, the news today that more clinical labs can start microbiome testing with GA-map® on MAGPIX® will fuel this growth and create more business opportunities.

CEO Ronny Hermansen comments:

“With this news we can now offer our GA-map® on an additional Luminex instrument platform, the MAGPIX® system. This further strengthens our commercial reach and enables GA to capitalize on all labs that already has the MAGPIX® system installed, but also give us an opportunity to offer a less costly option for customers that install the system for GA-map® testing only. This is in line with the Company’s expansion strategy.”

Christoph Cordes, Vice President, Licensed Technology Group Luminex, a DiaSorin Company comments:

“We are pleased that additional multiplex assays are validated for use on our MAGPIX® CE-IVD system, Luminex’s compact and most affordable xMAP® platform. The addition of the CE-marked GA-map® Dysbiosis Test kit will enable our MAGPIX® customers to add microbiome testing to their current test portfolio. This offering from GA will complement Luminex’s existing array of commercially available IVD kits.»

For more information on Genetic Analysis, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

This information is such information that Genetic Analysis AS is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 1 February 2022.

About Genetic Analysis

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs 23 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com

About Luminex Corporation, a DiaSorin company

At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at www.luminexcorp.com.

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasoringroup.com